CLINICAL TRIALS PROFILE FOR PAREMYD
✉ Email this page to a colleague
All Clinical Trials for PAREMYD
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04620213 ↗ | Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis | Completed | Ocuphire Pharma, Inc. | Phase 3 | 2020-11-18 | The objectives of this study are: - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine - To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) - To evaluate the safety of Nyxol - To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis |
| NCT05134974 ↗ | Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) | Not yet recruiting | Ocuphire Pharma, Inc. | Phase 3 | 2021-11-18 | The objectives of this study are: - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine - To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) - To evaluate the safety of Nyxol - To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis - To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling |
| NCT05223478 ↗ | Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects | Recruiting | Ocuphire Pharma, Inc. | Phase 3 | 2021-12-17 | The objectives of this study are: - To evaluate the safety of Nyxol in pediatric subjects - To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically induced mydriasis in pediatric subjects The Sponsor intends to use this study to evaluate Nyxol in pediatric subjects aged 3 to 11 for the indication "the treatment of pharmacologically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents, or a combination thereof." |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PAREMYD
Condition Name
Clinical Trial Locations for PAREMYD
Trials by Country
Clinical Trial Progress for PAREMYD
Clinical Trial Phase
Clinical Trial Sponsors for PAREMYD
Sponsor Name
